1. Abstract Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu–Osler–Weber disease is a rare autosomal dominant multisystem disease characterized by angiodysplastic lesions involving the skin, lungs, gastrointestinal tract, brain and liver.
1. Abstract 1.1. Aims: This review aims to provide an overview of candidate biomarkers derived from MS-based proteomics representing inflammation or fibrosis in NAFLD and ALD. DOI:http://dx.doi.org/10.47829/JJGH.2021.7502
1. Abstract Transplantation has become the method of choice for treatment of patients with irreversible severe liver dysfunction. Hepatic vein thrombosis is a potential vascular complication. DOI:http://dx.doi.org/10.47829/JJGH.2021.7501
1. Abstract 1.1. Background and Objectives: Endoscopic ultrasound (EUS) guided fine needle sampling has been proven as an effective modality for the evaluation of potentially malignant lesions.
1. Abstract Randomized controlled trials are the gold standard for eliminating bias in determining the efficacy and safety of medical products. However, the high costs, long duration, limited generalizability, and ethical or technical feasibility of RCTs have impelled investigators to look for real-world studies as alternatives.
1. Abstract Chronic hepatitis B virus (HBV) infection leads to a heavy disease burden globally, which is disproportionately high in Asia Pacific region. The currently available antiviral therapy can effectively suppress HBV replication but is not capable of eliminating the virus. Many new drugs aiming at HBV cure are under investigation in recent years, most …
1. Abstract For chronic hepatitis B (CHB) clinical trials, new challenges in the selection of the appropriate clinical endpoints were issued with the rapidly evolving concepts in designing, conducting and analyzing clinical trials.
1. Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) has become a significant health concern not only in the US but also worldwide due to the global obesity epidemic. DOI:http://dx.doi.org/10.47829/JJGH.2021.7403
1. Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) has increasingly become a common cause of liver cirrhosis, hepatocellular carcinoma, and liver-related death. Currently, there are no therapeutic drugs that have proven efficacy and safety through randomized controlled clinical trial.
1. Abstract With the increasingly global epidemic of obese and metabolic syndrome, non-alcoholic steatohepatitis (NASH) has become a growing common cause of cirrhosis, hepatocellular carcinoma, and end-stage liver disease.
The Japanese Journal of Gastroenterology and Hepatology accepts all kinds of manuscripts, such as research, studies, reviews, clinical images, editorials, commentaries, etc.
For Detailed quotations reach out submission@jajogh.jp
It depends on the length of the manuscript and the reviews and edits needed.
We will help you with as many reviews and edits as are required to make your manuscript perfect for publication.
A good impact factor for JJGH is 2.0 as per Journal Citations Reports of 2021.
Niigata, 7F Stork Building Kagamibashi, 1230-7, 7-bancho, Kamiookawamaedori, Chuo-ku, Niigata, 951-8068, Japan.
*2021 Journal unofficial Impact Factor was established by dividing the number of articles published in 2020 with the number of times they are cited in 2021 based on Google Scholar Citation Index database. If ‘X’ is the total number of articles published in 2020 and ‘Y’ is the number of times these articles were cited in indexed journals during 2021 then, journal impact factor = Y/X.
Copyright 2018-2024 All Rights Reserved.